This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue.


You are about to leave a GSK website

Third party content disclaimers


You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independently operated and not managed by GSK. The website you are linking to is not controlled or endorsed by GSK and GSK assumes no responsibility for the content on the website. If you wish to proceed, click "OK". If you do not wish to leave this website, click “CANCEL”.



FEV1, forced expiratory volume in one second;

Cardiovascular events, such as cardiac arrhythmias, may be seen after the administration of muscarinic recepter antagonists and sympatho-mimetic agents, including umeclidinium/vilanterol. Therefore, Anoro Ellipta should be used with caution in patients with severe cardiovascular disease. 5

Due to antimuscarinic activity (i.e. a LAMA class effect), Anoro Ellipta and Tiotropium should be used with caution in patients with urinary retention or narrow angle glaucoma. 56

Details of the blinding process for all tiotropium comparatory studies discusses in this web page can be found on page 474 in Decramer M et al. Lancet Respir Med 2014; 2:472-486,3 and page 2190 in Maleki-Yazdi M et al. Adv Ther 2016; 33:2188-21991
*Trough FEV1 improved by 252mL for Anoro (n=230) vs. 107mL for tiotropium (n=216)
**Reduced by 2.0 puffs/day for Anoro (n=776) vs. 1.4 puffs/day for tiotropium (n=764)
Number of subjects with analysable data at Day 169 based on a pooled post hoc subgroup analysis of three studies


  1. Maleki-Yazdi M et al. Adv Ther 2016; 33:2188-2199.
  2. GSK Data on file: RF/UCV/0112/15(1).
  3. Riley JH et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873–1880.
  4. Svedsater H et al. BMC Pulm Med 2013; 13:72.
  5. Anoro Ellipta Prescribing Information, Malaysia. Version v04.
  6. Tiotropium SmPC, 2018

Trade marks are owned by or licensed to the GSK group of companies.